Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) is a global biopharmaceutical company focused on innovative research and development of proprietary drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. Sucampo has a marketed product - AMITIZA® - and a pipeline including lifecycle management and clinical development programs. Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the United Kingdom.

Company Growth (employees)
Rockville, US
Size (employees)
139 (est)-12%
Sucampo Pharmaceuticals was founded in 1996 and is headquartered in Rockville, US

Sucampo Pharmaceuticals Office Locations

Sucampo Pharmaceuticals has offices in Rockville, Milton, Zug, Kita Ward and in 3 other locations
Rockville, US
Sanda-shi, JP
Chuo Ward, JP
Chiyoda, JP
Kita Ward, JP
Zug, CH
Milton, GB

Sucampo Pharmaceuticals Metrics

Sucampo Pharmaceuticals Summary

Market capitalization

$463.4 m

Closing share price

Sucampo Pharmaceuticals's current market capitalization is $463.4 m.

Sucampo Pharmaceuticals Financials

Sucampo Pharmaceuticals's revenue is $89.6 m in FY, 2013 which is a 22.4% decrease from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$89.6 m$115.5 m$153.2 m$230.1 m

Revenue growth, %


Gross profit

$77.2 m$99.2 m$116.4 m

Operating expense total

$68 m$72 m$72 m


$9.2 m$27.2 m$44.5 m

Net Income

$6.4 m$13.1 m$33.4 m$18.5 m

Operating cash flow

($7.9 m)$27.5 m$36.7 m

Sucampo Pharmaceuticals Market Value History

Sucampo Pharmaceuticals Online Presence

Sucampo Pharmaceuticals Company Life

You may also be interested in